• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫内膜癌临床I期和II期手术病理危险因素与预后的关系:一项妇科肿瘤学组研究

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

作者信息

Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, Graham J E

机构信息

Division of Gynecologic Oncology, University of Southern California Medical School, Los Angeles.

出版信息

Gynecol Oncol. 1991 Jan;40(1):55-65. doi: 10.1016/0090-8258(91)90086-k.

DOI:10.1016/0090-8258(91)90086-k
PMID:1989916
Abstract

Between June 20, 1977 and February 5, 1983, the Gynecologic Oncology Group entered 1180 women with clinical stage I or II (occult) endometrial carcinoma into a surgical-pathological staging study. Eight hundred ninety-five patients with endometrioid or adenosquamous carcinoma were evaluable for this study which relates surgical-pathological parameters and postoperative treatment to recurrence-free interval and recurrence site. Proportional hazards modeling of time to recurrence was performed. For patients without metastasis determined by surgical-pathological staging the greatest determinant of recurrence was grade 3 histology adenocarcinoma grade 3, relative risk (RR) = 15; adenosquamous carcinoma grade 3, RR = 8.1; all adenocanthomas, RR = 1.0). Of 48 patients with histologically documented aortic node metastases, 47 had one or more of the following features: (1) grossly positive pelvic nodes, (2) grossly positive adnexal metastasis, or (3) outer one-third myometrial invasion. Pelvic radiation was administered to 48.0% and vaginal brachytherapy alone to 10.2% of patients postoperatively; 41.8% received no adjuvant radiation therapy. None of three recurrences in the vaginal implant group were vaginal or pelvic; 7.4% (7 of 95) of recurrences in the pelvic radiation therapy (RT) group were vaginal and 16.8% were pelvic; 18.2% (8 of 44) of recurrences in the no adjuvant radiation group were vaginal and 31.8% pelvic. Because of the high degree of selection bias no valid comparisons can be made of recurrence-free interval in these groups. The 5-year recurrence-free interval for patients with negative surgical-pathological risk factors (other than grade and myoinvasion) was 92.7%; involvement of the isthmus/cervix 69.8%; positive pelvic cytology 56.0%; vascular space invasion 55.0%; pelvic node or adnexal metastases 57.8%; and aortic node metastases or gross laparotomy findings 41.2%. It is not clear that cervix invasion per se diminishes survival, because it is more often associated with poor tumor differentiation (34.7% versus 24.0%, grade 3) and deep myoinvasion (47.0 vs 18.6%) than cases without cervix invasion. The relapse rate among cervix-positive and -negative cases with grade 3 lesions and deep myoinvasion is not dramatically different (48.8% vs 39.8%). The proportion of failures which were vaginal/pelvic (34.6% for the surgery only group compared to 12.5% of the RT group) appears to favor the use of adjuvant radiation for patients with more than one-third myoinvasion and grade 2 or 3 tumor. There were 97 patients in the study group with malignant cytology of which 29.1% had regional/distant failure, which compares to 10.5% of the cytology-negative patients.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

1977年6月20日至1983年2月5日期间,妇科肿瘤研究组将1180例临床I期或II期(隐匿性)子宫内膜癌患者纳入一项手术病理分期研究。895例子宫内膜样癌或腺鳞癌患者可用于本研究,该研究将手术病理参数和术后治疗与无复发生存期及复发部位相关联。对复发时间进行了比例风险建模。对于经手术病理分期确定无转移的患者,复发的最大决定因素是3级组织学腺癌(3级,相对风险[RR]=15);腺鳞癌3级,RR=8.1;所有腺棘皮瘤,RR=1.0)。在48例有组织学记录的主动脉旁淋巴结转移患者中,47例具有以下一项或多项特征:(1)盆腔淋巴结大体阳性,(2)附件大体转移阳性,或(3)肌层外三分之一浸润。术后48.0%的患者接受盆腔放疗,10.2%的患者仅接受阴道近距离放疗;41.8%的患者未接受辅助放疗。阴道植入组的3例复发均不在阴道或盆腔;盆腔放疗(RT)组7.4%(95例中的7例)的复发在阴道,16.8%在盆腔;未接受辅助放疗组18.2%(44例中的8例)的复发在阴道,31.8%在盆腔。由于高度的选择偏倚,无法对这些组的无复发生存期进行有效比较。手术病理危险因素(除分级和肌层浸润外)为阴性的患者5年无复发生存率为92.7%;峡部/宫颈受累为69.8%;盆腔细胞学阳性为56.0%;血管间隙浸润为55.0%;盆腔淋巴结或附件转移为57.8%;主动脉旁淋巴结转移或大体剖腹探查结果为41.2%。宫颈浸润本身是否会降低生存率尚不清楚,因为与无宫颈浸润的病例相比,它更常与肿瘤分化差(34.7%对24.0%,3级)和深部肌层浸润(47.0对18.6%)相关。3级病变和深部肌层浸润的宫颈阳性和阴性病例的复发率没有显著差异(48.8%对39.8%)。阴道/盆腔失败的比例(仅手术组为34.6%,而RT组为12.5%)似乎支持对肌层浸润超过三分之一且肿瘤为2级或3级的患者使用辅助放疗。研究组中有97例患者细胞学为恶性,其中29.1%有区域/远处失败,而细胞学阴性患者为10.5%。(摘要截取自400字)

相似文献

1
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.子宫内膜癌临床I期和II期手术病理危险因素与预后的关系:一项妇科肿瘤学组研究
Gynecol Oncol. 1991 Jan;40(1):55-65. doi: 10.1016/0090-8258(91)90086-k.
2
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.子宫内膜I-IV期透明细胞癌的治疗结果及失败模式:对辅助放疗的意义
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1272-6. doi: 10.1016/s0360-3016(02)04404-8.
3
Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study.多柔比星作为高危子宫内膜癌(I期和隐匿性II期)患者手术和放射治疗后的辅助治疗:一项妇科肿瘤学组研究。
Gynecol Oncol. 1990 Feb;36(2):166-71. doi: 10.1016/0090-8258(90)90166-i.
4
Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients.子宫内膜腺癌综合放疗与手术治疗:437例患者的研究
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):81-97. doi: 10.1016/s0360-3016(00)01571-6.
5
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study.一项关于手术分期为IB期宫颈癌患者细胞类型的分析:妇科肿瘤学组研究
Gynecol Oncol. 1996 Dec;63(3):304-11. doi: 10.1006/gyno.1996.0327.
6
A prospective trial of postoperative vaginal radium/cesium for grade 1-2 less than 50% myometrial invasion and pelvic radiation therapy for grade 3 or deep myometrial invasion in surgical stage I endometrial adenocarcinoma.一项针对手术分期为I期子宫内膜腺癌的前瞻性试验,对于肌层浸润小于50%的1-2级患者采用术后阴道镭/铯治疗,对于3级或肌层深度浸润患者采用盆腔放射治疗。
Cancer. 1990 Sep 15;66(6):1133-8. doi: 10.1002/1097-0142(19900915)66:6<1133::aid-cncr2820660610>3.0.co;2-h.
7
Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.辅助性高剂量率阴道近距离放射治疗作为I期和II期子宫内膜癌的治疗方法。
Obstet Gynecol. 2002 Feb;99(2):235-40. doi: 10.1016/s0029-7844(01)01672-6.
8
Operable Stages IB and II cervical carcinomas: a retrospective study comparing preoperative uterovaginal brachytherapy and postoperative radiotherapy.可手术的IB期和II期宫颈癌:一项比较术前子宫阴道近距离放疗和术后放疗的回顾性研究。
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):780-93. doi: 10.1016/s0360-3016(02)02971-1.
9
Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.高剂量率阴道顶端放射治疗(192铱)联合化疗对Ⅰ期子宫浆液性乳头状癌的有效治疗
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):77-84. doi: 10.1016/s0360-3016(97)00581-6.
10
Survival and disease relapse in surgical stage I endometrioid adenocarcinoma of the uterus after adjuvant vaginal vault brachytherapy.辅助阴道穹窿近距离放疗后手术 I 期子宫内膜样腺癌的生存和疾病复发。
Int J Gynecol Cancer. 2010 May;20(4):564-9. doi: 10.1111/IGC.0b013e3181d7ce94.

引用本文的文献

1
Racial differences in endometrial cancer genomics and outcomes using UNCseq targeted DNA sequencing.使用UNCseq靶向DNA测序技术研究子宫内膜癌基因组学和预后的种族差异。
Gynecol Oncol Rep. 2025 Jun 25;60:101795. doi: 10.1016/j.gore.2025.101795. eCollection 2025 Aug.
2
Polyphenols as microRNA modulator in endometrial cancer: implications for apoptosis induction.多酚作为子宫内膜癌中的微小RNA调节剂:对诱导细胞凋亡的影响
Mol Genet Genomics. 2025 Mar 21;300(1):34. doi: 10.1007/s00438-025-02238-6.
3
Evaluation of the role of liver metastasectomy in the treatment of stage IV endometrial cancer.
肝转移瘤切除术在IV期子宫内膜癌治疗中的作用评估
J Gynecol Oncol. 2025 Sep;36(5):e79. doi: 10.3802/jgo.2025.36.e79. Epub 2025 Feb 11.
4
Paraaortic lymph node metastasis in endometrial cancer patients: a comprehensive analysis of rates, survival outcomes, and risk factors through systematic review and meta-analysis.子宫内膜癌患者的主动脉旁淋巴结转移:通过系统评价和荟萃分析对发生率、生存结局及危险因素进行的综合分析
Front Oncol. 2024 Oct 31;14:1490347. doi: 10.3389/fonc.2024.1490347. eCollection 2024.
5
Effects of Weight Loss on Key Obesity-Related Biomarkers Linked to the Risk of Endometrial Cancer: A Systematic Review and Meta-Analysis.体重减轻对与子宫内膜癌风险相关的关键肥胖生物标志物的影响:一项系统评价和荟萃分析。
Cancers (Basel). 2024 Jun 11;16(12):2197. doi: 10.3390/cancers16122197.
6
Intensity-modulated vaginal brachytherapy applicator and single- and multi-channel applicators in vaginal cuff brachytherapy.调强阴道近距离放射治疗施源器以及阴道断端近距离放射治疗中的单通道和多通道施源器
J Contemp Brachytherapy. 2024 Apr;16(2):132-138. doi: 10.5114/jcb.2024.138979. Epub 2024 Apr 18.
7
Efficacy of Single- and Dual-Docking Robotic Surgery of Paraaortic and Pelvic Lymphadenectomy in High-Risk Endometrial Cancer.单对接与双对接机器人手术在高危子宫内膜癌腹主动脉旁及盆腔淋巴结清扫中的疗效
J Pers Med. 2024 Apr 23;14(5):441. doi: 10.3390/jpm14050441.
8
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options.高级别子宫内膜癌:分子亚型、当前挑战和治疗选择。
Reprod Sci. 2024 Sep;31(9):2541-2559. doi: 10.1007/s43032-024-01544-5. Epub 2024 Apr 24.
9
Emerging Advances in Endometrial Cancer: Integration of Molecular Classification into Staging for Enhanced Prognostic Accuracy and Implications for Racial Disparities.子宫内膜癌的新进展:将分子分类纳入分期以提高预后准确性及对种族差异的影响
Cancers (Basel). 2024 Mar 16;16(6):1172. doi: 10.3390/cancers16061172.
10
The Clinical Relevance of Fractional Curettage in the Diagnostic Management of Primary Endometrial Cancer.分段刮宫术在原发性子宫内膜癌诊断管理中的临床意义。
Gynecol Obstet Invest. 2024;89(4):311-322. doi: 10.1159/000538268. Epub 2024 Mar 12.